Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Vx 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms VaxLung
- Sponsors Vaxon Biotech
- 23 Jun 2017 This trial has been discontinued in Greece (end date: 5 Mar 2017).
- 17 May 2017 This trial has been discontinued in Czech Republic (end date: 5 Mar 2017).
- 14 Apr 2017 The study has been Discontinued in Germany.